AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10601507
Drug: Electrophysiologically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysiologically guided therapy with antiarrhythmic drugs
Trial: 8109766
Drug: High-volume (HV)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume (HV) group: bupivacaine 0.125% with sufentanil 0.7 microgram/mL, 6-8 mL/h
Trial: 8109766
Drug: Low-volume (LV)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume (LV) group: bupivacaine 0.75% with sufentanil 4 micrograms/mL, 1.0-1.3 mL/h
Trial: 28615261
Drug: 10 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/d vitamin D3 supplementation
Trial: 28615261
Drug: 25 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg/d vitamin D3 supplementation
Trial: 28615261
Drug: 6 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 μg/d vitamin D intake
Trial: 28615261
Drug: 14 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 μg/d vitamin D intake
Trial: 28615261
Drug: 20 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg/d vitamin D intake
Trial: 28615261
Drug: 28 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 μg/d vitamin D intake
Trial: 28615261
Drug: 2 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg/d placebo
Trial: 22436144
Drug: Helical Tomotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helical Tomotherapy (HT) with a dose of 60 Gy/10 fractions
Trial: 15781547
Drug: Sevoflurane-propofol (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-propofol (8% sevoflurane + 1.5 mg/kg IV propofol)
Trial: 15781547
Drug: Propofol alone
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol alone (3 mg/kg IV)
Trial: 14685951
Drug: Short education
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short education program about the disorder and lithium therapy (3 sessions)
Trial: 10378490
Drug: Low-intensity laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity laser therapy (1.06 microm neodymium:yttrium-aluminum-garnet laser, 542mW/cm2)
Trial: 1430280
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education (OHE) programme with systematic brushing practice
Trial: 3155992
Drug: Nocardia rubra
RxNorm normalized name: Rhodotorula rubra
DrugBank: Rhodotorula rubra (DB10442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocardia rubra cell wall skeleton (N-CWS) treatment
Trial: 29298800
Drug: 0.2 mg/day
RxNorm normalized name: cloNIDine HCl 0.2 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/day pemafibrate
Trial: 29298800
Drug: 0.4 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/day pemafibrate
Trial: 19934787
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915)
Trial: 12407781
Drug: Perindopril/Indapamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril/Indapamide (2 mg/0.625 mg)
Trial: 7799021
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide phosphate (escalated from 50 mg/m2/d to 220 mg/m2/d for 5 days)
Trial: 7799021
Drug: Intravenous etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous etoposide phosphate
Trial: 7799021
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide phosphate
Trial: 7044798
Drug: Benoxaprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen (600 mg once a day)
Trial: 30609441
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg daily for 2 weeks)
Trial: 30609441
Drug: Amlodipine discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine discontinuation
Trial: 29132339
Drug: 3-day Cetrotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day Cetrotide sc injection (0.25 mg/day) started on Day-0
Trial: 29132339
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Cetrotide therapy)
Trial: 27998859
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate infusion at 5 mg·kg‐1·h‐1
Trial: 27998859
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate infusion and Saline (control group)
Trial: 12218276
Drug: Fluoridated topical
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated topical gel (12500 ppm F, partly as NaF, Olafluor and Dectafluor, pH 4.5) + fluoridated toothpaste (1450 ppm F as NaF)
Trial: 12218276
Drug: Fluoridated topical
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated topical gel + fluoridated toothpaste
Trial: 10800491
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including platin-compounds (cisplatin, carboplatin) and podophyllotoxins (etoposide, teniposide)
Trial: 10800491
Drug: Platin-containing regimens
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platin-containing regimens with new agents (gemcitabine, taxenes, navelbine)
Trial: 10800491
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and preirradiatory chemotherapy
Trial: 2354297
Drug: Regular surveillance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular surveillance using an activities of daily living questionnaire administered by volunteers
Trial: 403421
Drug: Intravenous Actovegin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Actovegin
Trial: 23333007
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 150 mg twice daily
Trial: 22308557
Drug: onabotulinumtoxinA (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onabotulinumtoxinA (second injection)
Trial: 19293358
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered every week or every other week, titrated to maintain hemoglobin within +/-1.0 g/dL of baseline values, with a target range of 9.0 - 12.0 g/dL for up to 24 weeks.
Trial: 3300565
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (PUVA + etretinate)
Trial: 22730343
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + etanercept or MTX + hydroxychloroquine + sulfasalazine triple therapy
Trial: 22730343
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with MTX with step-up to MTX + etanercept or to triple therapy if disease was still active at 24 weeks
Trial: 19781964
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Trial: 19781964
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Trial: 18431444
Drug: 4-site ID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-site ID regimen (0.1 ml at 4 ID sites on day 0, 0.1 ml ID at 2 sites on day 7, and at one site on days 28 and 90)
Trial: 18431444
Drug: 8-site ID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-site ID regimen (0.05 ml per ID site)
Trial: 18431444
Drug: 5-dose intramuscular
RxNorm normalized name: PAXLOVID 300 MG ; 100 MG (Day 1), 150 MG ; 100 MG (Days 2-5) Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-dose intramuscular regimen
Trial: 16483029
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of papaverine
Trial: 10508813
Drug: Spiros dry
RxNorm normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiros dry powder inhaler (90- and 270-microgram albuterol base)
Trial: 10508813
Drug: Ventolin metered
RxNorm normalized name: albuterol Metered Dose Inhaler [Ventolin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin metered dose inhaler (90- and 270-microgram albuterol base)
Trial: 10508813
Drug: Spiros dry
RxNorm normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiros dry powder inhaler and Ventolin metered dose inhaler
Trial: 30172032
Drug: Secretory leukocyte
RxNorm normalized name: Secretory leukocyte protease inhibitor (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secretory leukocyte protease inhibitor (SLPI)
Trial: 27440177
Drug: Hippotherapy (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (30 minutes once weekly for 12 consecutive weeks)
Trial: 21533812
Drug: AC/CAF chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC/CAF chemotherapy
Trial: 9716035
Drug: PVI 5-FU-based
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PVI 5-FU-based chemotherapy
Trial: 2663153
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Trial: 2663153
Drug: Controlled-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Trial: 2663153
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of trazodone
Trial: 2663153
Drug: Controlled-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulation of trazodone
Trial: 25496446
Drug: Migraine Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine Group (MG) - no treatment
Trial: 20535581
Drug: Xuefu Zhuyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefu Zhuyu Capsule (XFZY)
Trial: 20535581
Drug: Shengmai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai Capsule (SM)
Trial: 18272546
Drug: MMX mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalazine 2.4 g/day (once-daily dosing)
Trial: 18272546
Drug: MMX mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalazine 2.4 g/day (twice-daily dosing)
Trial: 14999298
Drug: DAC-7 (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAC-7 (daunorubicin 60 mg/m2/day, days 1-3; cytarabine 200 mg/m2/day, days 1-7; cladribine 5 mg/m2/day, days 1-5)
Trial: 9511845
Drug: Preference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference group (subjects choose their treatment)
Trial: 9511845
Drug: Randomized group
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized group (random allocation to treatment)
Trial: 2848053
Drug: CORT (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT (500 mg bolus injection within 5 s of the start of surgery)
Trial: 2848053
Drug: FENT (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENT (50-100 mg)
Trial: 2848053
Drug: CORT (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT (500 mg bolus injection) + FENT (50-100 mg)
Trial: 29076318
Drug: PDRN (5.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDRN (5.625 mg, 3 mL, intramuscular 5 days a week and perilesional 2 days a week)
Trial: 29076318
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline (3 mL)
Trial: 22831853
Drug: TOCAS 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOCAS 0.4 mg plus SOLI 6 mg
Trial: 22831853
Drug: TOCAS 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOCAS 0.4 mg plus SOLI 9 mg
Trial: 22333618
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guérin (BCG) treatment with PBMC culture
Trial: 16803740
Drug: Problem-Solving Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-Solving Therapy (PST) delivered by Master's trained social workers in a primary care setting
Trial: 8349933
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized cat extract (total dose approximately 4,500,000 allergy units)
Trial: 8349933
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized cat extract
Trial: 30517724
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A supplementation (VAS) of 10,000 IU weekly until 6 mo postpartum
Trial: 20708076
Drug: Mucoadhesive tablet
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucoadhesive tablet containing 24 μg clobetasol‐17 propionate (CP) applied 3 times a day for 4 weeks
Trial: 20708076
Drug: Commercial CP
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial CP ointment for cutaneous application (123 μg/application) mixed with Orabase™
Trial: 18534050
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg once daily for 28 days
Trial: 9051558
Drug: Erythromycin (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (333 mg three times daily for 10 days)
Trial: 3085560
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of epinephrine and aminophylline
Trial: 31356228
Drug: Cabazitaxel 20
RxNorm normalized name: cabazitaxel 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 20 mg/m (C20)
Trial: 28574378
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from atorvastatin to rosuvastatin after 6 months
Trial: 28574378
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and rosuvastatin (without switching)
Trial: 26571012
Drug: Inulin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (30 g/day for 2 weeks)
Trial: 11108415
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing 20 g of protein and 800 mg of calcium for 60 days
Trial: 8382934
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of OPC‐17116 (400 mg)
Trial: 8382934
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of OPC‐17116 (400 mg day‐1, twice daily, for 6.5 days)
Trial: 8382934
Drug: OPC‐17116 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC‐17116 (300 mg day‐1, three times daily, for 2 days)
Trial: 26209097
Drug: Risk factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factor guided multi-component intervention including medication adjustment, stepped care for anxiety/depression, and exercise therapy.
Trial: 20367790
Drug: CR-rhIFN-α(2b) 160
RxNorm normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR-rhIFN-α(2b) 160 μg every 2 weeks for 12 weeks with ribavirin
Trial: 20367790
Drug: CR-rhIFN-α(2b) 320
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR-rhIFN-α(2b) 320 μg every 2 weeks for 12 weeks with ribavirin
Trial: 20367790
Drug: CR-rhIFN-α(2b) 480
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR-rhIFN-α(2b) 480 μg every 2 weeks for 12 weeks with ribavirin
Trial: 20367790
Drug: CR-rhIFN-α(2b) 640
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR-rhIFN-α(2b) 640 μg every 2 weeks for 12 weeks with ribavirin
Trial: 12877758
Drug: β1-selective β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β1-selective β-blockers (nebivolol)
Trial: 1313078
Drug: L-threonine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threonine (2 g daily)
Trial: 31500139
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training with carbohydrate administration before each session
Trial: 31500139
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training without carbohydrate administration
Trial: 31500139
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training with carbohydrate administration
Trial: 28294318
Drug: Impact of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of Killing (IOK) treatment (N = 17)
Trial: 25728731
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonists (MRAs) therapy
Trial: 25728731
Drug: No MRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No MRA therapy
Trial: 24026142
Drug: hydrochlorothiazide (diuretic)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (diuretic)
Trial: 22174074
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of standardized extract from Ageratina pichinchensis
Trial: 16159535
Drug: 1-month tapering
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month tapering of antiepileptic drug
Trial: 16159535
Drug: 6-month tapering
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month tapering of antiepileptic drug
Trial: 1963701
Drug: CDDP 200
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 200 mg/m2 administered in arm A (100 mg/m2 on Day 1 and Day 8)
Trial: 1963701
Drug: CDDP 200
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 200 mg/m2 administered in arm B (40 mg/m2 per day during 5 consecutive days)
Trial: 24330656
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 21 mg transdermal nicotine patches for 8-12 weeks and withdrawal-oriented behavioural support for 7 sessions
Trial: 11330759
Drug: Second-line drugs
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line drugs treatment for six months
Trial: 19140498
Drug: Tibolone therapy
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone therapy (2.5 mg daily for 1 year)
Trial: 8571194
Drug: Rapid protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid protamine administration (1.5 mg/kg over 3 minutes)
Trial: 8571194
Drug: Slow protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow protamine administration (1.5 mg/kg over 15 minutes)
Trial: 1929241
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (0.25 mg/kg)
Trial: 1929241
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (1.5 mg/kg)
Trial: 31797473
Drug: Crocin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (30 mg/day)